{
    "clinical_study": {
        "@rank": "75472", 
        "acronym": "LBL-CISL-1", 
        "brief_summary": {
            "textblock": "Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens\n      for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with\n      high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment\n      outcome of hyper-CVAD in LBL has reported only in small number of patients from single\n      institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based\n      treatment in LBL."
        }, 
        "brief_title": "Hyper-CVAD Treatment in Lymphoblastic Lymphoma", 
        "condition": "Lymphoblastic Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD\n      regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment.\n      After achievement of response, patients either underwent hematopoietic stem cell\n      transplantation (HSCT) or consolidation with hyper-CVAD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age over 18 at diagnosis\n\n          -  Pathologically proven lymphoblastic lymphoma\n\n        Exclusion Criteria:\n\n          -  proven HIV infection\n\n          -  pretreatment with other regimens"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult lymphoblast lymphoma patients treated with hyper-CVAD regimen in Korea"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813344", 
            "org_study_id": "LBL-CISL-1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adult lymphoblastic lymphoma", 
            "Hyper-CVAD", 
            "first-line treatment"
        ], 
        "lastchanged_date": "March 14, 2013", 
        "location": {
            "contact": {
                "email": "geumsook@ajou.ac.kr", 
                "last_name": "Geum Sook Jeong, MS", 
                "phone": "+82-31-219-5990"
            }, 
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of", 
                    "state": "Kyeonggi", 
                    "zip": "443-721"
                }, 
                "name": "Ajou Universtiy School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma", 
        "overall_contact": {
            "email": "seonghyunmd@naver.com", 
            "last_name": "Seong Hyun Jeong, MD", 
            "phone": "+82-31-219-5989"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813344"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ajou University School of Medicine", 
            "investigator_full_name": "Seong Hyun Jeong", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "source": "Ajou University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ajou University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}